Jade Biosciences (JBIO) Price & Analysis

Compare

172 Followers

JBIO Stock Chart & Stats

$12.82

Market closed

$12.82

Day’s Range― - ―

52-Week Range$6.57 - $100.10

Previous CloseN/A

VolumeN/A

Average Volume (3M)127.19K

Market Cap

$293.64M

Enterprise Value$63.88M

Total Cash (Recent Filing)$198.91M

Total Debt (Recent Filing)$747.00K

Price to Earnings (P/E)―

Beta0.38

Next Earnings

May 18, 2026

EPS EstimateN/A

Last Dividend Ex-Date

Apr 29, 2025

Dividend Yield18.72%

Share Statistics

EPS (TTM)-0.48

Shares Outstanding32,626,730

10 Day Avg. Volume252,880

30 Day Avg. Volume127,195

Financial Highlights & Ratios

PEG Ratio53.52

Price to Book (P/B)-1.62K

Price to Sales (P/S)0.00

P/FCF Ratio-1.67K

Enterprise Value/Market Cap0.22

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-3.04K

Enterprise Value/Ebitda-1.02

Forecast

1Y Price Target

$22.00

Price Target Upside71.61% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Market OpportunityIgAN represents a large market opportunity that likely exceeds $10B in the US alone with limited treatment options that directly address the cause of the disease.

Pipeline ExpansionJade announced the expansion of its pipeline with the disclosure of its BAFF-R-targeting afucosylated antibody, JADE201.

Product DevelopmentJADE101 should achieve greater APRIL suppression and a >2x longer dosing interval than sibe, based on its ultra-high affinity and half-life extension.

Bears Say

Jade Biosciences News

Jade Biosciences initiated with a Buy at Clear Street

Clear Street analyst Kaveri Pohlman initiated coverage of Jade Biosciences (JBIO) with a Buy rating and $25 price...

6d ago

JBIO

Jade Biosciences price target raised to $17 from $14 at Guggenheim

Guggenheim raised the firm’s price target on Jade Biosciences (JBIO) to $17 from $14 and keeps a Buy...

12d ago

JBIO

Jade Biosciences files to sell 16.13M shares of common stock for holders

16:15 EST Jade Biosciences (JBIO) files to sell 16.13M shares of common stock for holders Published first on...

16d ago

JBIO

Jade Biosciences reports Q3 EPS (48c), consensus (67c)

“The third quarter marked meaningful progress toward our mission of delivering potentially best-in-class therapies for autoimmune diseases,” said...

17d ago

JBIO

Jade Biosciences Advances Autoimmune Therapies

Jade Biosciences, Inc. ( ($JBIO) ) has released its Q3 earnings. Here is a breakdown of the information...

16d ago

JBIO

Jade Biosciences Reports Q3 2025 Financial Results

Jade Biosciences ( ($JBIO) ) just unveiled an announcement. On April 28, 2025, Jade Biosciences, formerly Aerovate Therapeutics,...

16d ago

JBIO

Jade Biosciences: Promising Pipeline and Strategic Expansion Drive Buy Rating

TD Cowen analyst Tyler Van Buren has maintained their bullish stance on JBIO stock, giving a Buy rating...

17d ago

JBIO

Jade Biosciences Advances with Phase 1 Study of JADE101

Jade Biosciences, Inc. (($JBIO)) announced an update on their ongoing clinical study. Jade Biosciences, Inc. is conducting a...

1M ago

JBIO

Jade Biosciences initiated with a Buy at BTIG

BTIG initiated coverage of Jade Biosciences (JBIO) with a Buy rating and $28 price target APRIL inhibitors are...

2M ago

JBIO

Jade Biosciences up 16.5% at $10.65 after JADE201 announcement

07:50 EDT Jade Biosciences (JBIO) up 16.5% at $10.65 after JADE201 announcement Published first on TheFly – the...

2M ago

JBIO

Jade Biosciences Secures $135 Million in Private Placement

Jade Biosciences ( ($JBIO) ) just unveiled an update. On October 6, 2025, Jade Biosciences, Inc. entered into...

2M ago

JBIO

Jade Biosciences prices 13.4M shares at $9.14 in private placement

Jade Biosciences (JBIO) entered into a securities purchase agreement for a private investment in public equity financing that...

2M ago

JBIO

Jade Biosciences announces JADE201 afucosylated monoclonal antibody

Jade Biosciences (JBIO) unveiled JADE201, its investigational half-life extended, afucosylated monoclonal antibody targeting the B-cell activating factor receptor....

2M ago

JBIO

Jade Biosciences’ Chief Medical Officer Departs

Jade Biosciences ( ($JBIO) ) has provided an announcement. On September 9, 2025, Hetal Kocinsky, M.D. departed from...

3M ago

JBIO

JBIO FAQ

What was Jade Biosciences’s price range in the past 12 months?

Jade Biosciences lowest stock price was $6.57 and its highest was $100.10 in the past 12 months.

What is Jade Biosciences’s market cap?

Jade Biosciences’s market cap is $293.64M.

When is Jade Biosciences’s upcoming earnings report date?

Jade Biosciences’s upcoming earnings report date is May 18, 2026 which is in 169 days.

How were Jade Biosciences’s earnings last quarter?

Jade Biosciences released its earnings results on Nov 13, 2025. The company reported -$0.48 earnings per share for the quarter, beating the consensus estimate of -$0.671 by $0.191.

Is Jade Biosciences overvalued?

According to Wall Street analysts Jade Biosciences’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Jade Biosciences pay dividends?

Jade Biosciences pays a Notavailable dividend of $2.4 which represents an annual dividend yield of 18.72%. See more information on Jade Biosciences dividends here

What is Jade Biosciences’s EPS estimate?

Jade Biosciences’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Jade Biosciences have?

Jade Biosciences has 32,626,730 shares outstanding.

What happened to Jade Biosciences’s price movement after its last earnings report?

Jade Biosciences reported an EPS of -$0.48 in its last earnings report, beating expectations of -$0.671. Following the earnings report the stock price went up 10.537%.

Which hedge fund is a major shareholder of Jade Biosciences?

Currently, no hedge funds are holding shares in JBIO

Jade Biosciences Stock Smart Score

Neutral

Fundamentals

Return on Equity

-50.23%

Trailing 12-Months

Asset Growth

100.52%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Jade Biosciences

Jade Biosciences, Inc. is a biotechnology company focused on developing best-in-class therapies to address critical unmet needs in autoimmune diseases. Their lead asset, JADE-001, targets the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for the treatment of immunoglobulin A (IgA) nephropathy. JADE-001 is anticipated to enter clinical trials in the second half of 2025, with initial data expected in the first half of 2026. The company's pipeline also includes two preclinical antibody programs, JADE-002 and JADE-003.

Jade Biosciences (JBIO) Earnings & Revenues

Historic Earnings Reports

JBIO Stock 12 Month Forecast

Average Price Target

$22.00

▲(71.61% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","64":"$64","19.75":"$19.75","34.5":"$34.5","49.25":"$49.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":28,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$28.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":22,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$22.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$17.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,19.75,34.5,49.25,64],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.8,11.200000000000001,12.600000000000001,14,15.4,16.8,18.2,19.6,21,22.4,23.8,25.2,26.599999999999998,{"y":28,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.8,10.73846153846154,11.676923076923078,12.615384615384617,13.553846153846155,14.492307692307694,15.430769230769231,16.369230769230768,17.307692307692307,18.246153846153845,19.184615384615384,20.123076923076923,21.06153846153846,{"y":22,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.8,10.353846153846154,10.907692307692308,11.461538461538462,12.015384615384615,12.569230769230769,13.123076923076923,13.676923076923078,14.23076923076923,14.784615384615385,15.338461538461537,15.892307692307693,16.446153846153848,{"y":17,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":63.81,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.22,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.54,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.2,"date":1730419200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":9.69,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":8.88,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":9.18,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":10,"date":1746057600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":7.2,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.84,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.89,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.11,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.8,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >